Modification upon aging of the density of presynaptic modulation systems in the hippocampus.
Different presynaptic neuromodulation systems have been explored as possible targets to manage neurodegenerative diseases. However, most studies used young adult animals whereas neurodegenerative diseases are prevalent in the elderly. Thus, we now explored by Western blot analysis how the density of different presynaptic markers and receptors changes with aging in rat hippocampal synaptosomes (purified nerve terminals). Compared to synaptosomal membranes from 2-month-old rats, the density of presynaptic proteins (synaptophysin or SNAP-25) decreased at 18-24 months. In parallel, markers of glutamatergic terminals (vGluT1 or vGluT2) and cholinergic terminal markers (vAChT) constantly decreased with aging from 12 to 18 months onwards, whereas the densities of GABAergic (vGAT) only decreased after 24 months. Inhibitory A(1) and CB(1) receptor density tended to decrease with aging, whereas facilitatory mGluR5 and P2Y1 receptor density was roughly constant and facilitatory A(2A) receptor density increased at 18-24 months. Thus aging causes an imbalance of excitatory versus inhibitory nerve terminal markers and causes a predominant decrease of inhibitory rather than facilitatory presynaptic modulation systems.
Canas
Paula M
PM
Centre for Neuroscience of Coimbra, Institute of Biochemistry, Faculty of Medicine, University of Coimbra, Rua Larga, 3004-504 Coimbra, Portugal.
Duarte
João M N
JM
Rodrigues
Ricardo J
RJ
Köfalvi
Attila
A
Cunha
Rodrigo A
RA
D000367:Age Factors; D000375:Aging / Q000502:physiology*; D000818:Animals; D005786:Gene Expression Regulation / Q000502:physiology*; D006624:Hippocampus / Q000166:cytology*; D008297:Male; D017729:Presynaptic Terminals / Q000378:metabolism / Q000502:physiology*; D051381:Rats; D043705:Receptor, Adenosine A2A / Q000378:metabolism; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D018048:Receptors, Purinergic P2 / Q000378:metabolism; D058472:Receptors, Purinergic P2Y1; D016708:Synaptophysin / Q000378:metabolism; D050825:Synaptosomal-Associated Protein 25 / Q000378:metabolism; D050494:Vesicular Acetylcholine Transport Proteins / Q000378:metabolism; D050598:Vesicular Glutamate Transport Protein 1 / Q000378:metabolism; D050599:Vesicular Glutamate Transport Protein 2 / Q000378:metabolism; D050495:Vesicular Inhibitory Amino Acid Transport Proteins / Q000378:metabolism
C546383:P2ry1 protein, mouse; C546384:P2ry1 protein, rat; D043705:Receptor, Adenosine A2A; D043884:Receptor, Cannabinoid, CB1; D018048:Receptors, Purinergic P2; D058472:Receptors, Purinergic P2Y1; C493477:Slc17a6 protein, mouse; C493466:Slc17a7 protein, rat; D016708:Synaptophysin; D050825:Synaptosomal-Associated Protein 25; D050494:Vesicular Acetylcholine Transport Proteins; D050598:Vesicular Glutamate Transport Protein 1; D050599:Vesicular Glutamate Transport Protein 2; D050495:Vesicular Inhibitory Amino Acid Transport Proteins; C493406:vesicular GABA transporter